Literature DB >> 22555335

Dynamic evaluation and quantification of microvascularization during degradable starch microspheres transarterial Chemoembolisation (DSM-TACE) of HCC lesions using contrast enhanced ultrasound (CEUS): a feasibility study.

P Wiggermann1, W A Wohlgemuth, M Heibl, A Vasilj, M Loss, A G Schreyer, C Stroszczynski, E M Jung.   

Abstract

PURPOSE: To evaluate the time dependent changes of microcirculation in hepatocellular carcinoma (HCC) lesions during degradable starch microsphere (DSM)-TACE using contrast enhanced ultrasound (CEUS).
MATERIALS AND METHODS: A total of 48 CEUS examinations were performed (1-5 MHz, convex probe) in 6 selected patients who underwent DSM-TACE with EmboCept®S for the treatment of HCC lesions. I.v. application of ultrasound contrast media was performed before and 24 hours post embolization. In addition i.a. contrast application was performed via the angiographic catheter right before and after the embolization and during a follow up time of 2 hours every 30 minutes. The capillary circulation of the treated HCC lesions was analyzed and quantitative perfusion analysis was performed using a perfusion software by two experienced radiologists in consensus.
RESULTS: A significantly reduced microvascularization was seen right after DSM-TACE in all cases using CEUS. The reduction of PEAK, RBV (regional blood volume) and RBF (regional blood flow) compared to preembolization values was highly significant. Mean PEAK was 34.3 ± 13.1 prior to embolization and 9.4 ± 9.1 post embolization (p < 0.001). Mean RBV was 446.5 ± 122.4 prior to embolization and 70.9 ± 23.8 post embolization (p < 0.001). The corresponding figures for RBF were 34.7 ± 13.4 prior- and 4.8 ± 3.4 post embolization (p < 0.001). During follow up a stepwise revascularization of the lesions was documented: 90 minutes post embolization perfusion parameters were not significantly different from prae-embolization values.
CONCLUSION: In this feasibility study, capillary perfusion quantification of HCC lesions after DSM-TACE could be demonstrated using CEUS. Using quantitative perfusion analysis it was possible to quantify the transient embolizing effect of DSM-TACE.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22555335     DOI: 10.3233/CH-2012-1555

Source DB:  PubMed          Journal:  Clin Hemorheol Microcirc        ISSN: 1386-0291            Impact factor:   2.375


  11 in total

1.  [Interventional sonography of the liver and kidneys].

Authors:  D-A Clevert; E M Jung
Journal:  Radiologe       Date:  2013-11       Impact factor: 0.635

2.  TACE with degradable starch microspheres (DSM-TACE) as second-line treatment in HCC patients dismissing or ineligible for sorafenib.

Authors:  Roberto Iezzi; Maurizio Pompili; Emanuele Rinninella; Eleonora Annicchiarico; Matteo Garcovich; Lucia Cerrito; Francesca Ponziani; AnnaMaria De Gaetano; Massimo Siciliano; Michele Basso; Maria Assunta Zocco; GianLodovico Rapaccini; Alessandro Posa; Francesca Carchesio; Marco Biolato; Felice Giuliante; Antonio Gasbarrini; Riccardo Manfredi
Journal:  Eur Radiol       Date:  2018-08-31       Impact factor: 5.315

3.  Re: Baseline and Early MR Apparent Diffusion Coefficient Quantification as a Predictor of Response of Unresectable Hepatocellular Carcinoma to Doxorubicin Drug-Eluting Bead Chemoembolization.

Authors:  Fabrizio Chegai; Stefano Merolla; Laura Greco; Marco Nezzo; Lorenzo Mannelli; Antonio Orlacchio
Journal:  J Vasc Interv Radiol       Date:  2016-09       Impact factor: 3.464

4.  Intermediate hepatocellular carcinoma: the role of transarterial therapy.

Authors:  Fabrizio Chegai; Antonio Orlacchio; Stefano Merolla; Serena Monti; Lorenzo Mannelli
Journal:  Hepat Oncol       Date:  2015-10

Review 5.  [Contrast-enhanced ultrasound (CEUS) of the liver : Critical evaluation of use in clinical routine diagnostics].

Authors:  K Müller-Peltzer; J Rübenthaler; M Reiser; D-A Clevert
Journal:  Radiologe       Date:  2017-05       Impact factor: 0.635

Review 6.  Contrast-enhanced ultrasonography: advance and current status in abdominal imaging.

Authors:  Yong Eun Chung; Ki Whang Kim
Journal:  Ultrasonography       Date:  2014-09-12

7.  Focal Lesions in Fatty Liver: If Quantitative Analysis Facilitates the Differentiation of Atypical Benign from Malignant Lesions.

Authors:  Quan-Yuan Shan; Li-Da Chen; Lu-Yao Zhou; Zhu Wang; Guang-Jian Liu; Yang Huang; Wei Li; Jin-Ya Liu; Xiao-Yan Xie; Ming-de Lu; Jie Liu; Wei Wang
Journal:  Sci Rep       Date:  2016-01-04       Impact factor: 4.379

8.  Impact of Different Embolic Agents for Transarterial Chemoembolization (TACE) Procedures on Systemic Vascular Endothelial Growth Factor (VEGF) Levels.

Authors:  Andreas Schicho; Claus Hellerbrand; Kristina Krüger; Lukas P Beyer; Walter Wohlgemuth; Christoph Niessen; Ernst Hohenstein; Christian Stroszczynski; Philippe L Pereira; Philipp Wiggermann
Journal:  J Clin Transl Hepatol       Date:  2016-12-27

9.  Transarterial chemoembolization (TACE) with degradable starch microspheres (DSM) in hepatocellular carcinoma (HCC): multi-center results on safety and efficacy.

Authors:  Andreas Schicho; Philippe L Pereira; Michael Haimerl; Christoph Niessen; Katharina Michalik; Lukas P Beyer; Christian Stroszczynski; Philipp Wiggermann
Journal:  Oncotarget       Date:  2017-08-07

10.  Management of bleeding associated with radiofrequency ablation of benign thyroid nodules.

Authors:  Kunpeng Hu; Yufan Lian; Jinfen Wang; Wenchao Li; Zhicheng Yao; Bo Liu; Jie Ren
Journal:  J Int Med Res       Date:  2020-08       Impact factor: 1.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.